The content is available as a PDF (41.4 KB).
editorial . 2007 Oct;4(4):569–570. doi: 10.1016/j.nurt.2007.08.006
Neuroimmunotherapeutics comes of age
Richard M Ransohoff
1, Scott S Zamvil
2
Richard M Ransohoff
1Department of Neurosciences, Neuroinflammation Research Center Lerner Research Institute and Meilen Center for MS Treatment and Research Cleveland Clinic Foundation, 9500 Euclid Avenue, 44195 Cleveland, OH
Find articles by Richard M Ransohoff
Scott S Zamvil
2Department of Neurology and Program in Immunology, University of California, San Francisco, 513 Parnassus Avenue Rm. S-268, 94143 San Francisco, CA
Find articles by Scott S Zamvil
1Department of Neurosciences, Neuroinflammation Research Center Lerner Research Institute and Meilen Center for MS Treatment and Research Cleveland Clinic Foundation, 9500 Euclid Avenue, 44195 Cleveland, OH
2Department of Neurology and Program in Immunology, University of California, San Francisco, 513 Parnassus Avenue Rm. S-268, 94143 San Francisco, CA
© Springer New York 2007
PMCID: PMC7479683 PMID: 17920537